Find a Clinical Trial by Phase

Adult Cancers
Childhood Cancers
Doctor
Drug
Phase

New studies open frequently, please check back for updates

The following physicians have trials which are currently recruiting patients. If you do not see the doctor you are searching for, please call 310-423-2133 for more information.

Back to Phases

Phase: III

26 protocol(s) meet the specified criteria. Please click on the protocol number to get more information about the trial.

Doctor	Protocol No.	Title
Ayoub, Walid	GS-US-428-4194	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis
Burnison, C Michele	A221505	A221505: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction (RT Charm) (IRB#54882)
Chung, Jeffrey	EP0092	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate The Efficacy And Safety Of Padsevonil As Adjunctive Treatment Of Focal-Onset Seizures In Adult Subjects With Drug-Resistant Epilepsy
Daskivich, Timothy	EA8143	EA8143: A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (IRB#50240)
Faries, Mark	716-01	716-01: Adjuvant Therapy with Pembrolizumab versus Placebo in Resected Highrisk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE 716) (IRB#53866)
Figlin, Robert	17-214-09	17-214-09: A Phase 3 Randomized Open Label Study to Compare NKTR-214 Combined with Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients with Previously Untreated Advanced Renal Cell Carcinoma (IRB#57158)
Giuliano, Armando	AFT-25	AFT-25: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial (IRB#48166)
Gupta MD, Amit	IIT2019-03-ROSSER-BCA	IIT2019-03-ROSSER-BCA: A Novel Multiplex ELISA Assay for Surveilling Patients with a History of Bladder Cancer (IRB#57055)
Gupta MD, Amit	IIT2019-04-ROSSER-GH	IIT2019-04-ROSSER-GH: A Novel Multiplex ELISA Assay for Evaluating Patient with gross hematuria for bladder cancer (IRB#57056)
Gupta MD, Amit	IIT2019-05-ROSSER-MICROH	IIT2019-05-ROSSER-MICROH: A Novel Multiplex ELISA Assay for Evaluating Patients with Microscopic Hematuria for Bladder Cancer (IRB#57068)
Gupta MD, Amit	S1602	S1602: A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naïve High-Grade Non-Muscle Invasive Bladder Cancer (IRB#50035)
Gupta MD, Amit	S1806	S1806: Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer (IRB#384)
Gutierrez, Rodolfo	R2810-ONC-1788	R2810-ONC-1788: A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy In Patients with High Risk Cutaneous Squamous Cell Carcinoma (IRB#57958)
Hamid, Omid	587-00	587-00: A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial. (IRB#54410)
Hamid, Omid	MK-7902-003	MK-7902-003: A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) Versus Pembrolizumab Alone as First-line Intervention in Participants with Advanced Melanoma(LEAP-003) (IRB#56450)
Hendifar, Andrew	EIIT-MENAC-2017-03	EIIT-MENAC-2017-03: A Randomised, Open-Label Trial Of a Multimodal Intervention (Exercise, Nutrition And Antiinflammatory Medication) Plus Standard Care Versus Standard Care Alone to Prevent / Attenuate Cachexia in Advanced Cancer Patients Undergoing Chemotherapy (IRB#55738)
Majlessipour, Fataneh	AALL1731	AALL1731: A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy) (IRB#0140)
Majlessipour, Fataneh	AGCT1531	A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors (IRB#)
Majlessipour, Fataneh	ANBL1232	Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma (IRB#40692)
McArthur, Heather	BIG16-05/AFT-27/WO39391	BIG 16-05/AFT-27/WO39391: A Phase III, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer (IMPASSION030 AFT-27) (IRB#53409)
McArthur, Heather	MK3475-756	MK3475-756: A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2 ) Breast Cancer (IRB#57046)
Melmed, Gil	M16-000	A Multicenter, Randomized, Double-Blind, Placebo-Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991; or Completed M15-989
Natale, Ronald	MK-3475-789	MK3475-789: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789) (IRB#)
Patel, Jignesh	ALN-TTR02-011	APOLLO-B: A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)
Rimel, Bobbie Jo	3000-03-005/ENGOT-OV44	3000 03 005/ENGOT-OV44: A Randomized, Double-Blind, Phase 3 Comparison Of Platinum-Based Therapy With TSR 042 And Niraparib Versus Standard Of Care Platinum-Based Therapy As First Line Treatment Of Stage III Or IV Nonmucinous Epithelial Ovarian Cancer (FIRST) (IRB#54546)
Wentzel, Kristopher	8951-CL-0301	8951-CL-0301: A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of IMAB362 Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (IRB#53519)